Key takeaways

  • Compounded tirzepatide contains the same active ingredient as Mounjaro but may differ in quality, ingredients, and dosage.
  • The Food and Drug Administration (FDA) does not regulate the safety, effectiveness, or quality of compounded medications.
  • Compounded tirzepatide may be available when FDA-approved tirzepatide is in shortage or when Mounjaro cannot meet an individual’s medical needs.

Mounjaro is a brand-name prescription drug that contains the active ingredient tirzepatide. It is not available as a generic, but there may be cases where the active ingredient can be compounded.

Drug compounding is a process in which a licensed pharmacist creates a custom alternative to an FDA-approved drug. (You still need a doctor’s prescription to get compounded tirzepatide.)

Continue reading to learn what compounded tirzepatide is and how it compares with Mounjaro.

The compounded drug contains the same active ingredient as the FDA-approved drug. But it might differ from the FDA-approved drug in quality, ingredients, dosage, and form. So compounded tirzepatide is not the same as Mounjaro.

Dosage

The recommended starting dosage for Mounjaro is 2.5 milligrams (mg) once weekly. Your doctor may increase your dosage in increments up to a maximum dose of 15 mg once weekly.

Compounded tirzepatide has no standard dosage, and its dosage could differ from the dosage of Mounjaro. The FDA has received reports of side effects with compounded tirzepatide. These side effects might be due to the use of compounded tirzepatide doses that are higher than the prescribed doses for FDA-approved Mounjaro.

Side effects

The FDA has received reports of side effects that may relate to compounded tirzepatide. They are similar to those seen with Mounjaro:

  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • constipation

Cost

Some compounded drugs may be less expensive than FDA-approved drugs, but insurance may not cover compounded drugs.

Talk with your insurance provider or doctor about costs and possible coverage.

Effectiveness

Compounded tirzepatide has not undergone the same clinical testing as Mounjaro. This means compounded tirzepatide has no clinical evidence on its effectiveness for weight loss.

Mounjaro may reduce body weight in people with type 2 diabetes. But the FDA does not verify the effectiveness or safety of compounded tirzepatide.

Compounded tirzepatide is not approved by the FDA. This means the FDA does not regulate the safety, quality, or effectiveness of the drug. Instead, each state regulates its compounding pharmacies. Regulations for these pharmacies may vary from state to state.

Improper compounding practices may result in contamination or cause the drug to contain the wrong quantities of the active ingredient. Either situation could be dangerous.

In fact, the FDA has expressed concerns about compounded versions of GLP-1 drugs such as tirzepatide. Further, the FDA has received reports of negative side effects from compounded tirzepatide.

Unlike FDA-approved drugs, compounded tirzepatide won’t come with a package insert when the prescription is dispensed. It’s important to discuss using compounded tirzepatide with a doctor before you begin treatment with it.

A specialty pharmacy provides medications for complex health needs. Some specialty pharmacies or other state-licensed pharmacies may supply compounded tirzepatide. A licensed pharmacist may also compound drugs in a non-pharmacy facility.

Because compounded drugs are custom-made, a prescription for a compounded drug may take longer to fill than a prescription for an FDA-approved drug. It’s important to research a pharmacy before purchasing any compounded drugs. You can also ask a healthcare professional for their recommendations.

Reasons you may need to have an FDA-approved drug compounded

  • You have an allergy to an ingredient in the FDA-approved drug, which the compounded drug can avoid.
  • You cannot take the FDA-approved drug in its form (such as an injection) and need an alternative form.
  • The FDA-approved drug is not medically appropriate for you to take.
  • The FDA has declared a shortage of the FDA-approved drug and is allowing pharmacies to provide compounded versions.

Although shortages of brand-name tirzepatide injections have occurred, the FDA declared the shortage resolved in 2024. At that time, the FDA announced that compounding pharmacies could no longer produce compounded tirzepatide.

When an FDA-approved drug is in shortage, compounders are allowed to prepare compounded versions of it. If the drug is not in shortage, the FDA supports the use of the compounded drug only if an FDA-approved drug cannot meet an individual’s medical needs.

If FDA-approved tirzepatide injections return to the FDA’s drug shortage list, compounders may be able to make compounded tirzepatide again. If that happens, compounded tirzepatide must meet federal law conditions.

Below is a table with a quick comparison of compounded tirzepatide and Mounjaro.

Compounded tirzepatide
Mounjaro
Compounded tirzepatide
Mounjaro

no

yes

FDA does not regulate the safety, effectiveness, or quality of compounded drugs

safety, effectiveness, or quality regulated by the FDA

yes

yes

similar to Mounjaro

more common side effects are digestive side effects, such as nausea or vomiting

some compounded drugs may be less expensive, but insurance may not cover compounded drugs

depends on insurance coverage

Talk with your doctor about the risks and benefits of Mounjaro and compounded tirzepatide. If you cannot take Mounjaro for medical reasons, you may need compounded tirzepatide.

Disclaimer: While Healthline strives for factual, comprehensive, and current information, this article is not a substitute for a licensed healthcare professional’s expertise. Always consult a doctor before taking or discontinuing any medication. Drug information is subject to change and may not cover all uses, directions, precautions, warnings, interactions, reactions, or adverse effects. The lack of a warning does not guarantee a drug’s safety, effectiveness, or appropriateness for all patients or specific uses. Learn more about our approach to content integrity.